Skip to main content
SpringerLink
Log in

Proteases and Protease Inhibitors in Tumor Progression

  • Chapter
Chemistry and Biology of Serpins

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 425))

Abstract

Our understanding of the role of matrix degrading proteases in cancer has dramatically expanded over the last two decades. From correlative observations linking proteases to cancer progression, we have accumulated evidence supporting a causal role for proteases in various steps of tumor progression and have become increasingly aware of the complex interactions that exist among proteases. Specific natural inhibitors of these proteases have also been identified and their role as potent cytostatic agents in cancer has been suggested. In this article some of the concepts on the role of proteases in cancer are discussed and examples of cooperation between matrix metalloproteinases and the plasmin/plasminogen activators system are presented. The role of protease inhibitors such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and plasminogen activator inhibitor-2 (PAI-2) as inhibitors of tumor growth, invasion and metastasis is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67–68.

    Article  PubMed  CAS  Google Scholar 

  2. Liotta LA, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99–106.

    PubMed  CAS  Google Scholar 

  3. Sloane BF (1990) Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1: 137–152.

    PubMed  CAS  Google Scholar 

  4. DeClerck YA, Laug WE (1993) The role of the extracellular matrix in tumor invasion, metastasis and angiogenesis. In: Teicher BA (ed) Drug Resistance in Oncology. Marcel Dekker, NY, pp 121–163.

    Google Scholar 

  5. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197–250.

    PubMed  CAS  Google Scholar 

  6. Chambers AF, Colella R, Denhardt DT, Wilson SM (1992) Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog 5: 238–245.

    Article  PubMed  CAS  Google Scholar 

  7. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, Popovic T, Cotic V, Turk V (1992) Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 30: 69–74.

    PubMed  CAS  Google Scholar 

  8. Hahnel R, Harvey J, Robbins P, Sterrett G (1993) Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics. Anticancer Res 13: 2131–2135.

    PubMed  CAS  Google Scholar 

  9. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H (1993) Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer 29A: 1248–1251.

    Article  PubMed  CAS  Google Scholar 

  10. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer [see comments]. Hum Pathol 25: 857–862.

    Article  PubMed  CAS  Google Scholar 

  11. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H (1988) In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688–3692.

    PubMed  CAS  Google Scholar 

  12. Murphy G, Ward R, Gavrilovic J, Atkinson S (1992) Physiological mechanisms for metalloproteinase activation. Matrix Suppl 1: 224–230.

    PubMed  CAS  Google Scholar 

  13. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T (1993) Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178: 55–62.

    Article  PubMed  CAS  Google Scholar 

  14. Montgomery AM, DeClerck YA, Langley KE, Reisfeld RA, Mueller BM (1993) Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53: 693–700.

    PubMed  CAS  Google Scholar 

  15. Suzuki K, Lees M, Newlands GFJ, Nagase H, Woolley DE (1995) Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J 305: 301–306.

    PubMed  CAS  Google Scholar 

  16. Vassalli JD, Pepper MS (1994) Tumour biology. Membrane proteases in focus [news; comment]. Nature 370: 14–15.

    Article  PubMed  CAS  Google Scholar 

  17. Pei D,Weiss SJ(1996) Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 271: 9135–9140.

    Article  PubMed  CAS  Google Scholar 

  18. Lim YT, Sugiura Y, Laug WE, Sun B, Garcia A, DeClerck YA (1996) Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J Cell Physiol 167: 333–340.

    Article  PubMed  CAS  Google Scholar 

  19. Pei D, Weiss SJ (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375: 244–247.

    Article  PubMed  CAS  Google Scholar 

  20. DeClerck YA, Yean TD, Lee Y, Tomich JM, Langley KE (1993) Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem J 289: 65–69.

    PubMed  CAS  Google Scholar 

  21. Pei D, Majmudar G, Weiss SJ (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 269: 25849–25855.

    PubMed  CAS  Google Scholar 

  22. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM (1993) Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59: 329–341.

    Article  PubMed  CAS  Google Scholar 

  23. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS (1989) Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A 86: 8207–8211.

    Article  PubMed  CAS  Google Scholar 

  24. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583–4591.

    PubMed  CAS  Google Scholar 

  25. Strongin AY, Collier I, Bannikov, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase.Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331–5338.

    Article  PubMed  CAS  Google Scholar 

  26. DeClerck YA, Yean TD, Lu HS, Ting J, Langley KE (1991) Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J Biol Chem 266: 3893–3899.

    PubMed  CAS  Google Scholar 

  27. Kruithof EK, Baker MS, Bunn CL (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007–4024.

    PubMed  CAS  Google Scholar 

  28. Conese M, Blasi F (1995) Urokinase/urokinase receptor system: internalization/degradation of urokinaseserpin complexes: mechanism and regulation. Biol Chem Hoppe Seyler 376: 143–155.

    PubMed  CAS  Google Scholar 

  29. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA (1994) Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54: 5467–5473.

    PubMed  CAS  Google Scholar 

  30. Mueller BM, Yu YB, Laug WE (1994) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid mice. Proc Natl Acad Sci USA: 205–209.

    Google Scholar 

  31. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, Groom AC (1994) Over-expression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54: 4791–4797.

    PubMed  CAS  Google Scholar 

  32. Khokha R (1994) Suppression of the tumorigenic and metastatic abilities of murine B16–F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86: 299–304.

    Article  PubMed  CAS  Google Scholar 

  33. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FK (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087–2091.

    PubMed  CAS  Google Scholar 

  34. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726–4728.

    PubMed  CAS  Google Scholar 

  35. Brown PD (1994) Preclinical and clinical studies on the matrix metalloproteinase inhibitor, batimastat (BB-94). Clin Experimental Metastasis 12: 23 (Abstract).

    Google Scholar 

  36. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA (1996) Overexpression of tissue inhibitor of metalloproteinases-2 in vivo by retroviral mediated gene transfer inhibits tumor growth and invasion. Cancer Res 56: 2891–2895.

    PubMed  CAS  Google Scholar 

  37. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29–32.

    Article  PubMed  CAS  Google Scholar 

  38. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 107: 2373–2379.

    PubMed  CAS  Google Scholar 

  39. Stetler-Stevenson WG, Bersch N, Golde DW (1992) Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 296: 231–234.

    Article  PubMed  CAS  Google Scholar 

  40. Chesler L Golde DW, Bersch N, Johnson MD (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86: 4506–4515.

    PubMed  CAS  Google Scholar 

  41. Gan H, Newman GW, Remold HG (1995) Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. J Immunol 155: 1304–1315.

    PubMed  CAS  Google Scholar 

  42. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380–32388.

    PubMed  CAS  Google Scholar 

  43. Waltz DA, Sailor LZ, Chapman HA (1993) Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 91: 1541–1552.

    Article  PubMed  CAS  Google Scholar 

  44. DeClerck YA, Imren S (1994) Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170–2180.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Pediatrics, USA

    Yves A. DeClerck MD, Suzan Imren & Walter E. Laug

  2. Department of Biochemistry and Molecular Biology, Childrens Hospital Los Angeles, University of Southern California, Los Angeles, California, 90027, USA

    Yves A. DeClerck MD

  3. Department of Immunology, The Scripps Research Institute, La Jolla, California, 92037, USA

    Anthony M. P. Montgomery, Barbara M. Mueller & Ralph A. Reisfeld

Authors
  1. Yves A. DeClerck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzan Imren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony M. P. Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara M. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ralph A. Reisfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walter E. Laug
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves A. DeClerck MD .

Editor information

Editors and Affiliations

  1. University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

    Frank C. Church

  2. University of California, Irvine, California, USA

    Dennis D. Cunningham

  3. Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, Michigan, USA

    David Ginsburg

  4. Duke University and Durham VA Medical Centers, Durham, North Carolina, USA

    Maureane Hoffman

  5. Late of Monash University, Clayton, Victoria, Australia

    Stuart R. Stone

  6. Washington University School of Medicine, St. Louis, Missouri, USA

    Douglas M. Tollefsen

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

DeClerck, Y.A., Imren, S., Montgomery, A.M.P., Mueller, B.M., Reisfeld, R.A., Laug, W.E. (1997). Proteases and Protease Inhibitors in Tumor Progression. In: Church, F.C., Cunningham, D.D., Ginsburg, D., Hoffman, M., Stone, S.R., Tollefsen, D.M. (eds) Chemistry and Biology of Serpins. Advances in Experimental Medicine and Biology, vol 425. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5391-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5391-5_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7461-9

  • Online ISBN: 978-1-4615-5391-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation